Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation

摘要: The introduction into clinical practice of KRAS mutational status for selection patients has dramatically improved the results from use anti-EGFR monoclonal antibodies cetuximab or panitumumab metastatic colorectal cancer. More refined by means other molecular alterations, example BRAF, PIK3CA, and NRAS enabled further increases in responses to first-line therapy disease. Elucidation differences among specific subtypes mutations affecting sensitivity, identification mechanisms which tumor cell resistance is acquired, revealing “druggable” targets overcome resistance, are clearly a priority research. Recent data have revealed potentially different activity G13D mutation conferring cetuximab. This review examines most recent evidence available on codon 13 cancer, including both preclinical data, indicating between analyzing its prognostic predictive EGFR-targeted therapy.